Celldex Therapeutics
CLDX
148 hedge funds and large institutions have $1.03B invested in Celldex Therapeutics in 2014 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 43 reducing their positions, and 13 closing their positions.
100% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 13
10% more funds holding
Funds holding: 135 → 148 (+13)
9% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 43
6% less call options, than puts
Call options by funds: $24.4M | Put options by funds: $25.9M
22% less capital invested
Capital invested by funds: $1.31B → $1.03B (-$283M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$7.38M |
| 2 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
+$5.15M |
| 3 |
Axa
Paris,
France
|
+$4.9M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.88M |
| 5 |
First Eagle Investment Management
New York
|
+$3.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
-$11.8M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$11.5M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$8.57M |
| 4 |
AC
Apex Capital
Orinda,
California
|
-$8.28M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$5.44M |
CLDX Hedge Fund Activity: Q3 2014 in Review
148 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2014, worth a combined $1.03B — down 22% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CLDX positions and 13 closed out — a net gain of 13 holders — while 47 added to existing stakes and 43 trimmed.
The largest buyer was Tekla Capital Management, opening a new position worth an estimated $7.38M. The largest seller was TSP Capital Management Group, exiting entirely with an estimated $11.8M sold.
- 148 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2014, up from 135 in Q2 2014.
- Funds reported $1.03B of Celldex Therapeutics stock for Q3 2014, down 22% quarter-over-quarter.
- 26 funds opened new Celldex Therapeutics positions in Q3 2014 and 13 closed out, a net change of +13 holders.
- The largest Celldex Therapeutics buyer in Q3 2014 was Tekla Capital Management, an estimated $7.38M added.
- The largest Celldex Therapeutics seller in Q3 2014 was TSP Capital Management Group, an estimated $11.8M sold.
Based on aggregated 13F filings for Q3 2014.